021-51111890
购物车（）
sales@molnova.cn
Adoprazine
CAS No. 222551-17-9
Adoprazine ( SLV313 )
产品货号. M26047 CAS No. 222551-17-9
Adoprazine is a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥956 | 有现货 |
|
| 5MG | ￥1596 | 有现货 |
|
| 10MG | ￥2730 | 有现货 |
|
| 25MG | ￥4771 | 有现货 |
|
| 50MG | ￥6796 | 有现货 |
|
| 100MG | ￥9396 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Adoprazine
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Adoprazine is a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties.
-
产品描述Adoprazine is a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties.
-
同义词SLV313
-
通路Others
-
靶点Other Targets
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number222551-17-9
-
分子量405.5
-
分子式C24H24FN3O2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESFc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Zhang Z, Lunter DJ. Confocal Raman microspectroscopy as an alternative to differential scanning calorimetry to detect the impact of emulsifiers and formulations on stratum corneum lipid conformation. Eur J Pharm Sci. 2018 May 15. pii: S0928-0987(18)30232-X. doi: 10.1016/j.ejps.2018.05.013. [Epub ahead of print] PubMed PMID: 29775655.
产品手册
关联产品
-
3,4,7,8-Tetramethoxy...
3',4',7,8-Tetramethoxyflavone has antioxidant activity.
-
Ipamorelin 2acetate(...
Ipamorelin 2acetate is a growth-hormone-releasing peptide, induces longitudinal bone growth in rats.In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6 (ECs) = 1.3+/-0.4nmol/l and Emax = 85+/-5% vs 2.2+/-0.3nmol/l and 100%).
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
